The next step for CNIO, which has been running a drug - discovery program since 2005, would be to look for c -
RAF kinase inhibitors as potential cancer drugs.
Not exact matches
The
Raf ‐ 1
kinase inhibitor protein participates in the pathogenesis of IL ‐ 17 ‐ mediated autoimmune diseases and inflammation by promoting the formation of the IL ‐ 17RA ‐ Act1 complex, required for downstream signaling and cytokine production.
Moreover, these ATP - competitive
inhibitors induce the formation of B -
RAF and C -
RAF dimers, leading to extracellular signal — regulated
kinase (ERK) activation in diverse cancer cell types (23).